ElliotNorryMDFACP

Internal Medicine • Philadelphia, PA

Gastroenterology

Adaptimmune, Chief Medical Officer

Join to view full profile

Dr. Norry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Norry's full profile

Already have an account?

Office
351 Rouse Blvd
Philadelphia, PA 19112
Phone+1 215-825-9260

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Gastroenterology, 1993 - 1995
Temple University HospitalResidency, Internal Medicine, 1989 - 1992
New York University School of MedicineClass of 1989

Certifications & Licensure

PA State Medical License 1991 - 2024

Publications & Presentations

PubMed

14 citations
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia
Lancet. 2024-04-13
1 citations
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
Kewen He, David S Hong, Danxia Ke, Partow Kebriaei, Tianjiao Wang
Melanoma Research. 2023-08-01
58 citations
Autologous T cell therapy for MAGE-A4solid cancers in HLA-A*02patients: a phase 1 trial.
David S Hong, Brian A Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L Johnson
Nature Medicine. 2023-01-01

Journal Articles

Fludarabine and Neurotoxicity in Engineered T-cell Therapy
Elliot Norry, Crystal L Mackall, Nature

Press Mentions

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-Cel in Synovial Sarcoma - Response Rate and Durability Remain ConsistentNovember 18th, 2022
Adaptimmune Reports Positive Results from Its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOSNovember 11th, 2021
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC MeetingsOctober 5th, 2021
Join now to see all